New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareRetatrutide vs Palmitoyl Dipeptide-6

Retatrutide vs Palmitoyl Dipeptide-6

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Retatrutide
Skin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6
Summary
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
Half-Life
~10–12 days
Not applicable (topical)
Admin Route
SubQ
Topical
Research
Typical Dose
0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
0.005–0.05% in formulation
Frequency
Once weekly
Once or twice daily
Key Benefits
  • ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
  • Superior to both semaglutide and tirzepatide in early trial comparisons
  • Triple receptor mechanism addresses multiple obesity pathways
  • Significant reduction in liver fat (MASH/NAFLD indication being studied)
  • Improved cardiovascular and metabolic markers
  • Once-weekly dosing
  • Potential for greatest weight loss of any currently investigated compound
  • Increases skin firmness and density
  • Stimulates fibronectin and collagen IV production
  • Strengthens the dermal-epidermal junction
  • Reduces skin sagging in mature skin
  • Improves skin texture and smoothness
  • Supports extracellular matrix integrity
Side Effects
  • Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
  • Diarrhea
  • Constipation
  • Heart rate increase (from glucagon receptor agonism)
  • +2 more
  • Generally well-tolerated
  • Rare mild skin irritation in sensitive individuals
  • No known systemic effects at cosmetic concentrations
Stacks With